BioPharmX Announces Violet™ Iodine Now Available at Leading National Retailer
IT'S TIME FOR WOMEN TO SAY GOODBYE TO BREAST DISCOMFORT
MENLO PARK, Calif., March 10, 2015 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX), makers of Violet™ iodine, the new, once-daily, non-prescription pill for the relief of premenstrual breast discomfort, today announced the first-of-its-kind product has added a major U.S. drugstore chain to its retail partners. The daily supplement is available now and will be offered exclusively in the feminine care aisle.
"We continue to expand the national availability of Violet iodine to help provide relief to the nearly 37.5 million women in America who suffer from premenstrual breast discomfort," said BioPharmX President, Anja Krammer. "We hope more women will now discover an alternative to living with unnecessary pain."
"While Violet iodine is a daily supplement, it is conveniently available and readily found in the feminine care aisle where women are already shopping for other menstrual-related needs," adds Krammer. "We want women to know they no longer just have to 'deal with it' – now there is a solution with Violet iodine."
Let's talk − find us on Facebook and Twitter.
About Fibrocystic Breast Condition (FBC)
Fibrocystic breast condition is thought to be caused by hormonal imbalances, which can cause breast tissue growth to exceed its natural cell turnover. Breast tissue builds up month after month with each menstrual cycle, resulting in swollen, achy and tender breasts.
About Violet™ Iodine
Violet iodine is a daily iodine supplement for the relief of the most common symptoms of cyclic mastalgia and fibrocystic breast condition (FBC), including monthly swelling, tenderness, aches and heaviness. Violet iodine is available for sale at select CVS pharmacies and online at cvs.com, drugstore.com, and walgreens.com. To learn more about Violet iodine, visit www.VioletDaily.com and follow us on Facebook and Twitter.
About BioPharmX Corporation
BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the fast-growing health and wellness markets, including women's health, dermatology, and otolaryngology (ears, nose & throat). To learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
Statements in this news release relating to the business of BioPharmX, which are not historical facts, are "forward-looking statements." These forward-looking statements may be identified by words such as "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company's filings with the Securities and Exchange Commission (SEC). These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risk that the company's efforts to distribute Violet™ iodine through CVS Health's retail locations is unsuccessful. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
BioPharmX and Violet are pending trademarks of BioPharmX Inc. All other brand and product names are trademarks or registered trademarks of their respective holders.
SOURCE BioPharmX Corporation
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article